ConductScience.org, home

Paper36908849

Emerging Therapeutic Targets for Portal Hypertension.

Felli E and 5 others. Curr Hepatol Rep, 2023. Cited by 17 papers, by iCite.

Cite this record

ConductScience Library. Emerging Therapeutic Targets for Portal Hypertension. Papers, record 36908849. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36908849

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Emerging Therapeutic Targets for Portal Hypertension.
PubMed
Journal
Curr Hepatol Rep
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
17
iCite
Relative citation ratio, by iCite
1.57
iCite
Revised in PubMed
2023-03-14
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Felli EErichttps://orcid.org/0000-0002-5664-6746
2Nulan YYelidousi
3Selicean SSonia
4Wang CCong
5Gracia-Sancho JJordi
6Bosch JJaumehttps://orcid.org/0000-0003-3414-0055

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References205

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131563219Pharmacologic Management of Portal Hypertension.Clin Liver Dis2019https://conductscience.org/library/papers/31563219PubMed
223216382Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.J Gastroenterol Hepatol2013https://conductscience.org/library/papers/23216382PubMed
319157625Angiogenesis in liver disease.J Hepatol2009https://conductscience.org/library/papers/19157625PubMed
433128017Molecular and cellular mechanisms of liver fibrosis and its regression.Nat Rev Gastroenterol Hepatol2021https://conductscience.org/library/papers/33128017PubMed
510347107Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats.Hepatology1999https://conductscience.org/library/papers/10347107PubMed
634165199Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension.Aliment Pharmacol Ther2021https://conductscience.org/library/papers/34165199PubMed
730905652Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis.Gastroenterology2019https://conductscience.org/library/papers/30905652PubMed
829099421Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.Eur J Gastroenterol Hepatol2018https://conductscience.org/library/papers/29099421PubMed
934606912Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?J Hepatol2022https://conductscience.org/library/papers/34606912PubMed
1028953991Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats.Braz J Med Biol Res2017https://conductscience.org/library/papers/28953991PubMed
1122365955Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice.Life Sci2012https://conductscience.org/library/papers/22365955PubMed
1222806357Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent.Hepatology2012https://conductscience.org/library/papers/22806357PubMed
138995940Long course and prognostic factors of virus-induced cirrhosis of the liver.Am J Gastroenterol1997https://conductscience.org/library/papers/8995940PubMed
1431607677Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Gastroenterol Hepatol2020https://conductscience.org/library/papers/31607677PubMed
1517016424Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.Nat Rev Drug Discov2006https://conductscience.org/library/papers/17016424PubMed
1626406236Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis.PLoS One2015https://conductscience.org/library/papers/26406236PubMed
1735120736Baveno VII - Renewing consensus in portal hypertension.J Hepatol2022https://conductscience.org/library/papers/35120736PubMed
1825500203KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins.Gut2015https://conductscience.org/library/papers/25500203PubMed
1924232462Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.Nat Rev Immunol2013https://conductscience.org/library/papers/24232462PubMed
2033106416Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF-κB/NLRP3 inflammasome circuit.Proc Natl Acad Sci U S A2020https://conductscience.org/library/papers/33106416PubMed

See all 205 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.

PMIDTitleJournalYearIn PapersSource
41659769Carvedilol decreases hepatic vascular resistance by reducing fibrogenesis and reversing endothelial dysfunction in cirrhotic rats.JHEP Rep2026https://conductscience.org/library/papers/41659769PubMed
41024757Advances in portal hypertension management: Evolution of the Baveno guidelines.World J Gastroenterol2025https://conductscience.org/library/papers/41024757PubMed
40689145Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease.JHEP Rep2025https://conductscience.org/library/papers/40689145PubMed
40404839Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease.Nat Rev Gastroenterol Hepatol2025https://conductscience.org/library/papers/40404839PubMed
40069401Cirrhotic cardiomyopathy: comprehensive insights into pathophysiology, diagnosis, and management.Heart Fail Rev2025https://conductscience.org/library/papers/40069401PubMed
40044498Vasomics of the liver.Gut2025https://conductscience.org/library/papers/40044498PubMed
39997697From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.Metabolites2025https://conductscience.org/library/papers/39997697PubMed
39870944Preventing the progression of cirrhosis to decompensation and death.Nat Rev Gastroenterol Hepatol2025https://conductscience.org/library/papers/39870944PubMed
39859028Joint Group and Multi Institutional Position Opinion: Cirrhotic Cardiomyopathy-From Fundamentals to Applied Tactics.Medicina (Kaunas)2024https://conductscience.org/library/papers/39859028PubMed
39640222Mechanisms and implications of recompensation in cirrhosis.JHEP Rep2024https://conductscience.org/library/papers/39640222PubMed
38860875Microarray analysis demonstrates up-regulation of the endothelin-1 gene with compensatory down-regulation of the ETA receptor gene in human portal vein.Biosci Rep2024https://conductscience.org/library/papers/38860875PubMed
38447532Examining the therapeutic landscape of beta-blockers in portal hypertension.Clin Mol Hepatol2024https://conductscience.org/library/papers/38447532PubMed

Download CSV of cited by

Genes38

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AGT183PubTator's text mininghttps://conductscience.org/library/genes/183NCBI Gene
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213NCBI Gene
CNR11268PubTator's text mininghttps://conductscience.org/library/genes/1268NCBI Gene
CNR21269PubTator's text mininghttps://conductscience.org/library/genes/1269NCBI Gene
EDN11906PubTator's text mininghttps://conductscience.org/library/genes/1906NCBI Gene
EPHB22048PubTator's text mininghttps://conductscience.org/library/genes/2048NCBI Gene
GCG2641PubTator's text mininghttps://conductscience.org/library/genes/2641NCBI Gene
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740NCBI Gene
GLP2R9340PubTator's text mininghttps://conductscience.org/library/genes/9340NCBI Gene
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene
JAK13716PubTator's text mininghttps://conductscience.org/library/genes/3716NCBI Gene
JAK23717PubTator's text mininghttps://conductscience.org/library/genes/3717NCBI Gene
KDR3791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
KIT3815PubTator's text mininghttps://conductscience.org/library/genes/3815NCBI Gene
KLF210365PubTator's text mininghttps://conductscience.org/library/genes/10365NCBI Gene
LEPR3953PubTator's text mininghttps://conductscience.org/library/genes/3953NCBI Gene
LGALS33958PubTator's text mininghttps://conductscience.org/library/genes/3958NCBI Gene
LOXL24017PubTator's text mininghttps://conductscience.org/library/genes/4017NCBI Gene
MAP2K75609PubTator's text mininghttps://conductscience.org/library/genes/5609NCBI Gene
MAS1L116511PubTator's text mininghttps://conductscience.org/library/genes/116511NCBI Gene

See all 38 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36908849

GET https://conductscience.org/api/papers/v1/36908849/references?page=2